The clinical management of chondrosarcoma.
Chondrosarcomas (CHS) represent a heterogeneous group of disorders ranging from indolent, low-grade tumors to aggressive, high-grade forms. Surgical resection represents the primary and preferred treatment modality for individuals with localized disease. Radiation therapy is appropriate for the treatment of positive surgical margins or palliation of disease-related symptoms. The treatment of advanced, metastatic disease is particularly challenging given the recognition that conventional chemotherapy has proven to be largely ineffective. Systemic chemotherapy may be considered in variant forms such as mesenchymal or dedifferentiated chondrosarcomas but high-quality data supporting its use is limited. There is universal agreement, however, that novel treatment strategies are desperately needed. This review will highlight the need for a coordinated multidisciplinary approach to optimize the management and care of patients.
Riedel
Richard F
RF
Division of Medical Oncology, Department of Internal Medicine, Duke University Medical Center, Durham, NC 27710, USA. richard.riedel@duke.edu
Larrier
Nicole
N
Dodd
Leslie
L
Kirsch
David
D
Martinez
Salutario
S
Brigman
Brian E
BE
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D002813:Chondrosarcoma / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D002986:Clinical Trials as Topic; D019468:Disease Management; D006801:Humans; D010166:Palliative Care; D011379:Prognosis; D011859:Radiography; D018714:Radiotherapy, Adjuvant / Q000379:methods; D035703:Therapies, Investigational; D016896:Treatment Outcome